Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine

References

• Ivanyi LM, Wilton JMA, Lehner T. Cell-mediated immunity in periodontal disease; cytotoxicity, migration inhibition and lymphocyte transformation studies. Immunology. 1972; 22: 141–5.
   Web of Science ®Google Scholar
• Taubman MA, Yoshie H, Ebersole JL, Smith DJ, Olson CL. Host response in experimental periodontal disease. J Dent Res. 1984; 63: 455–60. 10.3402/jom.v4i0.19227.
   Web of Science ®Google Scholar
• Fullmer H, Gibson WA. Collagenolytic activity in gingivae of man. Nature (London). 1966; 209: 728–9. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Gross J, LaPiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci (USA). 1962; 48: 1014–21. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Ryan ME, Golub LM. Modulation of matrix metalloproteinase activity in periodontitis as a treatment strategy. Periodontology. 2000; 24: 226–38. 10.3402/jom.v4i0.19227.
   Google Scholar
• Jeffcoat MK, Reddy MS, Haigh S, Buchanan W, Doyle MJ, Meredith MP, et al.. A comparison of topical ketorolac, systemic flurbiprofen and placebo for the inhibition of bone loss in adult periodontitis. J Periodontol. 1995; 66: 329–38. 10.3402/jom.v4i0.19227.
   Google Scholar
• Serhan CN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol. 2008; 79: 1520–6. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol. 2002; 73: 813–22. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Caton J, Ryan ME. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacolog Res. 2011; 63: 114–20. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Golub LM, Ciancio S, Ramamurthy NS, Leung M, McNamara TF. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res. 1990; 25: 321–30. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998; 12: 2–26. 10.3402/jom.v4i0.19227.
   Google Scholar
• Ramamurthy NS, Zebrowski EJ, Golub LM. Collagenolytic activity of alloxan diabetic rat gingivae. Diabetes. 1973; 22: 272–4.
   Web of Science ®Google Scholar
• Golub LM, Lee HM, Lehrer G, Nemiroff A, Mcnamara TF, Kaplan R, et al.. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Periodontal Res. 1983; 18: 516–26. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Golub LM, Greenwald RA, Ramamurthy NS, McNamara TF, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Revs Oral Biol Med. 1991; 2: 297–322.
   PubMedGoogle Scholar
• Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP-mediated events in diabetes. Ann NY Acad Sci. 1999; 878: 311–34. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Golub LM, McNamara TF, D'Angelo G, Greenwald RA, Ramamurthy NS. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res. 1987; 66: 1310–4. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Preshaw PM, Novak MJ, Mellonig J, Magnusson I, Polson A, Giannobile WV, et al.. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008; 79: 445–52. 10.3402/jom.v4i0.19227.
   Google Scholar
• Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008; 7: 573–6.
   PubMed Web of Science ®Google Scholar
• Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al.. Effects of sub-antimicrobial dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003; 139: 459–64. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacolog Res. 2011; 63: 130–45. 10.3402/jom.v4i0.19227.
   Web of Science ®Google Scholar
• Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS malignancy consortium study. J Clin Oncol. 2006; 24: 1389–93. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Richards C, Pantanowitz L, Dezube BJ. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials. Pharmacolog Res. 2011; 63: 151–6. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Golub LM. Introduction and background, in special issue: clinical applications of non-antibacterial tetracyclines. Pharmacolog Res. 2011; 63: 97–156. 10.3402/jom.v4i0.19227.
   Google Scholar
• Carney DE, Lutz CJ, Picone AL, Gatto LA, Ramamurthy NS, Golub LM, et al.. A matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation. 1999; 100: 400–6. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Steinberg J, Gatto L, Schiller H, Lee HM, Halter J, Carney D, Golub L, et al.. Chemically-modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock. 2005; 24: 348–56. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Roy SK, Kubiak BD, Albert SP, Vieau CJ, Gatto L, Golub L, et al.. Chemically-modified tetracycline-3 prevents acute respiratory distress syndrome in a porcine model of sepsis plus ischemia/reperfusion lung injury. Shock. 2012; 37: 424–32. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gu Y, Lee HM, Hambardjieva E, Vranková K, Golub LM, et al.. Design, synthesis and biologic activity of new polyenolic inhibitors of matrix metalloproteinases. Curr Med Chem. 2012; in press.
   Web of Science ®Google Scholar
• Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001; 65: 232–60. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Walker C, Thomas J, Nangó S, Lennon J, Wetzel J, Powala C. Long-term treatment with sub-antimicrobial dose doxycycline exerts no antibacterial effect on the subginigval microflora associated with adult periodontitis. J Periodontol. 2000; 71: 1465–71. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Thomas J, Walker C. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol. 2000; 71: 1472–83. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Thomas JG, Metheny RJ, Karakiozis JM, Wetzel JM, Crout RL. Long-term sub-antimicrobial doxycycline (Periostat) as adjunctive management in adult periodontitis: effects on subgingival bacterial population dynamics. Adv Dent Res. 1998; 12: 32–9. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Marsh P, Martin MV. Oral microbiology4th ed. Wright. Oxford, 1999; 115–7.
   Google Scholar
• Preshaw PM, Hefti AH, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol. 2004; 31: 697–707. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Walker C, Preshaw PM, Novak J, Hefti AH, Bradshaw M, Powala C. Long-term treatment with sub-antimicrobial dose doxycycline has no effect on the intestinal flora. J Clin Periodontol. 2005; 32: 1163–9. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al.. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. J Fam Pract. 2003; 52: 594–7.
   Google Scholar
• Walker C, Puumala S, Golub LM, Stoner JA, Reinhardt RA, Lee H-M, et al.. Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiology results. J Periodontol. 2007; 78: 1590–601. 10.3402/jom.v4i0.19227.
   Google Scholar
• Stoller NH, Johnson LR, Trapnell S, Harrold CQ, Garrett S. The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. J Periodontol. 1998; 69: 1085–91. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Sedlacek M, Walker C. Antibiotic resistance in an in vitro subgingival biofilm model. Oral Microbiol Immunol. 2007; 22: 333–9. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Donlan RM. Role of biofilms in antimicrobial resistance. ASAIO J. 2000; 46: S47–52. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002; 15: 167–93. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for Pseaudomonas aerugionosa biofilm antibiotic reistance. Nature. 2003; 426: 306–10. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001; 358: 135–8. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Golub LM, Goodson JM, Lee HM, Vidal AM, McNamara TF, Ramamurthy NS. Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems. J Periodontol. 1985; 56: S93–7. 10.3402/jom.v4i0.19227.
   Google Scholar
• Lee HM, Cianci SG, Tuter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial-dose doxycycline efficacy as a matrix metalloproteinase inhibitor is enhanced when combined with an NSAID. J Periodontol. 2004; 75: 453–63. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, et al.. Subantimicrobial dose doxycycline as an adjunct to scaling and root planing: post-treatment effects. J Clin Periodontol. 2001; 28(8): 782–9. 10.3402/jom.v4i0.19227.
   Google Scholar
• Emingil G, Gürkan A, Atilla G, Kantarci A. Subantimicrobial-dose doxycycline and cytokine-chemokine levels in gingival crevicular fluid. J Periodontol. 2011; 82: 452–61. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Eady EA, Cove JH, Holland KT, Cunliffe WJ. Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. Br J Dermatol. 1990; 122: 233–44. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Heimdahl A, Nord CE. Influence of doxycycline on the normal flora and colonization of the oral cavity and colon. Swed Dent J. 1983; 7: 199–204.
   Google Scholar
• Fiehn NE, Westergaard J. Doxycycline-resistant bacteria in periodontally diseased individuals after resistant bacteria in periodontally diseases individuals after systemic doxycycline therapy and in healthy individuals. Oral Microbiol Immunol. 1990; 5: 219–22. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Rams TE, Babalola OO, Slots J. Subgingival occurrence of enteric rods, yeasts and staphylococci after systemic doxycycline therapy. Oral Microbiol Immunol. 1990; 5: 166–8. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Kornman KS, Karl EH. The effect of long-term low-dose tetracycline therapy on the subgingival microflora in refractory adult periodontitis. J Periodontol. 1982; 3: 604–10. 10.3402/jom.v4i0.19227.
   Google Scholar
• Ashley RA. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. SDD clinical research team. Ann N Y Acad Sci. 1999 30; 878: 335–46. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• McNamara TF, Golub LM, Yu Z, Ramamurthy NS. Reduced doxycycline blood levels in humans fail to promote resistant organisms. In Conf on Periodont Disease: pathogenesis and host immune responses. 1990; abstract #B54 (Conference Proceedings), Page 100, Osaka, Japan.
   Google Scholar
• Barnett M. Changing paradigms in periodontal therapy: host modulation with subantimicrobial dose doxycycline. Oral Health. 2007; 53–65.
   Google Scholar
• Ciancio S, Ashley R. Safety and efficacy of sub-antimicrobial-dose doxycycline therapy in patients with adult periodontitis. Adv Dent Res. 1998; 12: 27–31. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Payne JB, Golub LM. Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol Res. 2011; 63: 121–9. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol. 2008; 79: S1592–600. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol. 2003; 8: 12–37. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Preshaw PM, Hefti AF, Bradshaw MH. Adjunctive subantimicrobial dose doxycycline in smokers and non-smokers with chronic periodontitis. J Clin Periodontol. 2005; 32: 610–6. 10.3402/jom.v4i0.19227.
   Google Scholar
• Sgolastra F, Petrucci A, Gatto R, Giannoni M, Monaco A. Long-term efficacy of subantimicrobial-dose doxycycline as an adjunctive treatment to scaling and root planing: a systematic review and meta-analysis. J Periodontol. 2011; 82: 1570–81. 10.3402/jom.v4i0.19227.
   Google Scholar
• Novak MJ, Johns LP, Miller RC, Bradshaw MH. Adjunctive benefits of subantimicrobial dose doxycycline in the management of severe, generalized, chronic periodontitis. J Periodontol. 2002; 73: 762–9. 10.3402/jom.v4i0.19227.
   Google Scholar
• Novak MJ, Dawson DR, Magnusson I, Karpinia K, Polson A, Ryan ME, et al.. Combining host modulation and antimicrobial therapy in the management of moderate to severe periodontitis: a randomized, multi-center trial. J Periodontol. 2008; 79: 33–41. 10.3402/jom.v4i0.19227.
   Google Scholar
• Goldberg MB, Golub LM, Lee HM, Tenebaum HC. Assessing the effects of subantimicrobial-dose doxycycline/flurbiprofen on refractory periodontal disease. J Den Res. 2010; 89: abstract # 1176.
   Google Scholar
• Cohen DM, Lee HM, Bhattacharyya I, Sensat ML, Payne JB, Golub LM. Effective treatment for cicatricial pemphigoid using a novel combination therapy. J Dent Res. 2000; 79(Spec. Issue): 627.
   Google Scholar
• Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, et al.. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 2000; 102: 647–55. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Weinberg MA. New applications of doxycycline hyclate in medicine and dentistry. US Pharmacist. 2004.
   Google Scholar
• Stechmiller J, Cowan L, Schultz G. The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. Biol Res Nurs. 2010; 11: 336–44. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Chin GA, Thigpin TG, Perrin KJ, Moldawer LL, Schultz GS. Treatment of chronic ulcers in diabetic patients with the topical metalloproteinase inhibitor, doxycycline. Wounds. 2003; 15: 315–23.
   Web of Science ®Google Scholar
• Greenwald RA. The road forward: the scientific basis for tetracycline treatment of arthritic disorders. Pharmacolog Res. 2011; 64: 610–13. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, et al.. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arth Rheum. 2006; 54: 621–7. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, et al.. Tetracycline inhibit human synovial collagenase both in vitro and in vivo. J Rheumatol. 1987; 14: 28–32.
   PubMed Web of Science ®Google Scholar
• Zernicke R, Wohl G, Greenwald RA, Moak SA, Leng W, Golub LM. Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis. J Rheumatol. 1997; 24: 1324–31.
   Web of Science ®Google Scholar
• Leung MK, Greenwald RA, Ramamurthy NS, Moak SA, Koszulinski R, Dieudonne D, et al.. Tenidap and flurbiprofen enhance the uptake of matrix metalloproteinase inhibitor 4-dedimethyloamino tetracycline inflamed joints of adjuvant arthritic rats. J Rheumatol. 1995; 22: 1726–31.
   Google Scholar
• Brandt KD. Modification by oral doxycycline administration of articular cartilage breakdown in steoarthritis. J Rheumatol. 1995; 43: 149–51.
   Google Scholar
• Smith GN, Yu LP, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol. 1998; 25: 532–5.
   PubMed Web of Science ®Google Scholar
• Israel HA, Ramamurthy NS, Greenwald RA, Golub LM. The potential role of doxycycline in the treatment of osteoarthritis of the temporomandibular joint. Adv Dent Res. 1998; 12: 51–5. 10.3402/jom.v4i0.19227.
   Google Scholar
• Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006; 354: 2621–2. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Matsui K, Takeda K, Yu Z-X, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000; 124: 267–75.
   PubMed Web of Science ®Google Scholar
• Engebretsen SP, Hey-Hadavi J. Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: a pilot study. Pharmacolog Res. 2011; 64: 624–9. 10.3402/jom.v4i0.19227.
   Google Scholar
• Ryan ME, Ramamurthy NS, Golub LM. Tetracyclines inhibit protein glycation in experimental diabetes. Adv Dent Res. 1998; 12: 152–8. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Golub LM, Ramamurthy NS, Llavaneras A, Ryan ME, Lee HM, Liu Y, et al.. A chemically modified non-antimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats. Ann NY Acad Sci. 1999; 878: 290–310. 10.3402/jom.v4i0.19227.
   Google Scholar
• Sasaki T, Ramamurthy NS, Golub LM. Tetracycline administration increases collagen synthesis in osteoblasts of diabetic rats: a quantitative autoradiographic study. Calc Tiss Int. 1992; 50: 411–9. 10.3402/jom.v4i0.19227.
   Google Scholar
• Gomes BC, Golub LM, Ramamurthy NS. Tetracyclines inhibit parathyroid hormone-induced bone resorption in tissue culture. Experentia. 1984; 40: 1273–4. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Golub LM, Ramamurthy NS, McNamara TF, Gomes B, Wolff M, Casino A, et al.. Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. J Periodontal Res. 1984; 19: 651–5. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Bain S, Ramamurthy NS, Impeduglia T, Scolman S, Golub LM, Rubin C. Tetracycline prevents cancellous bone loss and maintains near-normal rates of bone formation in streptozotocin diabetic rats. Bone. 1997; 21: 147–53. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Craig RG, Yu Z, Xu L, Barr R, Ramamurthy N, Boland J, et al.. A chemically modified tetracycline inhibits streptozotocin-induced diabetic depression of skin collagen synthesis and steady-state type I procollagen Mrna. Biochim Biophys Acta. 1998; 1402: 250–60. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Williams S, Wakisaka A, Zeng QQ, Barnes J, Martin G, Wechter WJ, et al.. Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone. 1996; 19: 637–44. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Williams S, Wakisaka A, Zeng QQ, Barnes J, Seyedin S, Martin G, et al.. Effect of minocycline on osteoporosis. Adv Dent Res. 1998; 12: 71–5. 10.3402/jom.v4i0.19227.
   PubMedGoogle Scholar
• Payne JB, Reinhardt RA, Nummikoski PV, Golub LM. Doxycycline effects on oral bone loss in postmenopausal women. J Dent Res. 2001; 80: (special issue A), abstract no. 159.
   Google Scholar
• Crout RJ, Lee HM, Schroeder K, Crout H, Ramamurthy NS, Wiener M, et al.. The ‘cyclic’ regimen of low-dose doxycycline for adult periodontitis: a preliminary study. J Periodontol. 1996; 67: 506–14. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Stoner JA, Sorsa T, Reinhardt RA, Wolff MS, et al.. Doxycycline effects on serum bone biomarkers in postmenopausal women. J Dent Res. 2010; 89: 644–9. 10.3402/jom.v4i0.19227.
   Google Scholar
• Golub LM, Greenwald RA. Preface: clinical applications of non-antibacterial tetracycline. Part II. Pharmacolog Res. 2011; 64: 549–50. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998; 28: 1082–93. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation. 2009; 119: 2209–16. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Ann Revs Pharmacol Toxicol. 2007; 46: 211–42. 10.3402/jom.v4i0.19227.
   Google Scholar
• Meier CR, Derby LE, Jikk SS, Vasilakis C, Jick H. Antibiotic and risk of subsequent first-time acute myocardial infarction. JAMA. 1999; 281: 427–31. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Glen L. Antibiotic use and risk of myocardial infarction. Letters. JAMA. 1999; 282: 1997. 10.3402/jom.v4i0.19227.
   Google Scholar
• Golub LM, Greenwald RA, Thompson RW. Tetracycline use and risk of acute myocardial infarction. Letter. JAMA. 1999; 282: 1997–8. 10.3402/jom.v4i0.19227.
   Google Scholar
• Grayston JT, Kronmol RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005; 352: 1637–45. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al.. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005; 352: 1646–54. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler ThrombVasc Biol. 2004; 24: 733–8. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar
• Tuter G, Kurtis B, Serdar M, Aykan T, Okyay K, Yucel A, et al.. Effects of scaling and root planing and sub-antimicrobial dose doxycycline on oral and systemic biomarkers of disease in patients with both chronic periodontitis and coronary artery disease. J ClinPeriodontol. 2007; 34: 673–81. 10.3402/jom.v4i0.19227.
   Google Scholar
• Payne JB, Golub LM, Stoner JA, Lee HM, Reinhardt RA, Sorsa T, et al.. The effect of subantimicrobial dose doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. JADA. 2011; 142: 262–73.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AMJr, Kastelein JJ, et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195–207. 10.3402/jom.v4i0.19227.
   PubMed Web of Science ®Google Scholar